TNXP
Tonix Pharmaceuticals Holding Corp.
NASDAQ · Healthcare · Biotechnology · US
$10.87
−4.82%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$11.43
From 52W high−61.68%
Volume794045.00
Market cap$186.43M
P/E (TTM)—
P/S (TTM)6.4x
Div yield—
Key dataSep 18, 2026
Open
$11.43
From 52W high
−61.68%
Volume
794045.00
Market cap
$186.43M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.1x
P/E (TTM)
—
RSI (14)
34.4
MomentumView details →
1D Return
−4.82%
YTD Return
−28.27%
SummaryUpdated Jun 1, 2026
Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) is a clinical-stage biopharmaceutical company founded in 2007 and headquartered in Chatham, New Jersey. The company went public in May 2012 and focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics across multiple therapeutic areas. Tonix operates as a development-stage company with a diverse pipeline of drug candidates targeting immunology, rare diseases, infectious diseases, and central nervous system conditions, though it has yet to bring any products to market and remains in the clinical development phase.
Similar companies
Latest newsMore news →
Tonix Pharmaceuticals promoted Thomas Englese to Chief Commercial Officer, effective immediately on September 8, 2026.12d agoTonix Pharmaceuticals is focusing on the commercial launch of TONMYA for fibromyalgia.33d agoDr. Seth Lederman was appointed Interim Chief Medical Officer of Tonix Pharmaceuticals Holding Corp., effective August 18, 2026, while continuing as President, Chief Executive Officer and Chairman of the Board.34d ago